Zanubrutinib plus rituximab for MALT lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for people with MALT lymphoma that is advanced (stage III or IV) or has come back after local treatment. The goal is to see if this two-drug combination can shrink or control the lymphoma with fewer side effects than traditional chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have MALT lymphoma (a type of slow-growing lymphoma that starts in the lining of organs like the stomach, lungs, or eyes).
- The lymphoma must be newly diagnosed at stage III or IV, or have come back after local treatment (like surgery or radiation).
- You should not have had any previous systemic anti-lymphoma therapy (except for H. pylori treatment for stomach MALT).
- You must be at least 18 years old and in generally good health (able to do daily activities with only minor help).
- You must have at least one measurable tumor that can be seen on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, orelabrutinib and zuberitamab, as a first treatment for marginal zone lymphoma (MZL). It aims to see if this combination works well for patients who have not had systemic therapy before.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
Hear when a new Mucosa-associated Lymphoid Tissue Lymphoma (MALT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.